CORCEPT THERAPEUTICS INC
For the period ended Sep 30, 2026. Filed Nov 3, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2026 · Filed Nov 3, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
ITEM 5. OTHER INFORMATION
Insider Trading Arrangements
During the three months ended September 30, 2026, none of our directors and officers (as defined in Rule 16a-1(f) under the Exchange Act)adopted orterminated any contract, instruction or written plan for the purchase or sale of our securities that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, or any “non-Rule 10b5-1 trading arrangement,” as defined in Item 408(a) of Regulation S-K, other than as set forth in the table below. Each trading arrangement in the table below is intended to satisfy the affirmative defense of Rule 10b5-1(c).
| Name | Position | Action | Adoption Date | Total Shares of Common Stock to be Sold | Expiration Date(1) |
|---|---|---|---|---|---|
| Daniel N. Swisher, Jr. | Director | Adoption | 8/3/2026 | Up to 180,000 | 10/31/2027 |
| Atabak Mokari | Chief Financial Officer | Adoption | 8/13/2026 | Up to 200,000 | 11/14/2027 |
| William Guyer | Chief Development Officer | Adoption | 8/20/2026 | Up to 360,000 | 5/31/2028 |
| (1) | Each trading arrangement permits transactions through and including the earlier to occur of (a) the completion of all sales or (b) the date listed in the table. |
| Roberto Vieira, our President, Oncology, was appointed as an officer, as defined in Rule 16a-1(f) under the Exchange Act, effective as of September 1, 2026. Mr. Vieira adopted a Rule 10b5-1 trading arrangement on June 17, 2026, prior to his appointment as an officer. As Mr. Vieira was not an officer subject to the disclosure requirements of Item 408(a) of Regulation S-K at the time of adoption of this trading arrangement, no disclosure of this 10b5-1 plan was made in our Quarterly Report on Form 10-Q for the quarter ended June 30, 2026, and no such disclosure has been made in the table above. |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.